Cellebrite: 3 Key Takeaways for Long-Term Investors
Redomiciling to the U.S. in 2027 targets government sales delays, yet the article leaves open how much new business that actually unlocks.
Cellebrite, a digital forensics provider, reported robust financials in its third-quarter 2026 earnings call, with annual recurring revenue (ARR) soaring 20% year over year to $528.5 million. Management highlighted the launch of Genesis, an AI-driven investigative software tool, which generated $2 million in ARR in its first full quarter alone.
The company is also set to redomicile to the United States in the first half of 2027 to enhance purchasing ease and gain eligibility for major U.S. stock indices. However, upgrades to Inseyt, the flagship mobile device forensic extraction software, are expected to deliver lighter uplift in the final quarter compared to prior periods, as reported by Chief Financial Officer David Barter.
The company's free cash flow margin is anticipated to reach approximately 30% for the full year, fueled by subscription revenue making up 91% of total sales, according to Barter.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
